Li Tian, Sun Xiangzhou, Liu Yifan
Department of Urology, The Fifth Affiliated Hospital of Guangzhou Medical University Guangzhou 510700, Guangdong, China.
Minimally Invasive Technique and Product Translational Center, Guangzhou Medical University Guangzhou 510700, Guangdong, China.
Int J Clin Exp Pathol. 2017 Dec 1;10(12):11415-11424. eCollection 2017.
The aim of study was to investigate the expression of microRNA-27b in different prostate tissues and its anti-tumor effects in prostate cancer.
Measuring the expression of microRNA-27b, evaluating the PI3K protein expression in 28 benign prostatic hyperplasia and 63 prostate cancer tissues, analyzing the correlation between miRNA-27b and PI3K, and miRNA-27b's correlation with Gleason Grading and clinical stages were analyzed. We divided the prostate cancer patients into two groups: low group and high group, comparing the overall survival and progression free survival. In the cell experiment, the PC3 was divided into three groups: NC group, BL group and miRNA group. The cells of difference groups were measuring the cell proliferation, apoptosis and cycle and evaluating PI3K, AKT and P21 protein expressions of difference groups.
The microRNA-27b expression of prostate cancer significantly increased Compared with benign prostatic hyperplasia (). The PI3K protein expression of prostate cancer tissues were significantly enhanced compared with benign prostatic hyperplasia. The PI3K protein expression was positive correlation with miRNA-27b in cancer tissues. Furthermore, the microRNA-27b expression was significantly correlated with the Gleason Grading and clinical stages in prostate cancer (). The patients with higher miR-27b expression level had both poorer overall survival and progression free survival. In cell experiment, the cell proliferation of miRNA group was significantly lower than NC group (); the cell apoptosis and G1 phase of miRNA group were significantly difference compared with NC group (); Compared with NC group, PI3K, AKT and P21 protein expressions were significantly down-regulation in miRNA group ().
miR-27b was up-regulated in prostate cancer tissue compared with benign prostatic hyperplasia tissues, and its expression level was correlated with a variety of important clinical pathological parameters. In the treatment of prostate cancer, miR-27b inhibition had effects to suppress prostate cancer proliferation by regulation PI3K/AKT/P21 signaling pathway. Moreover; miR-27b may serve as a promising biomarker for predicting the prognosis of prostate cancer.
本研究旨在探讨微小RNA-27b在不同前列腺组织中的表达及其在前列腺癌中的抗肿瘤作用。
检测28例良性前列腺增生组织和63例前列腺癌组织中微小RNA-27b的表达,评估PI3K蛋白表达,分析miRNA-27b与PI3K的相关性,以及miRNA-27b与Gleason分级和临床分期的相关性。将前列腺癌患者分为低表达组和高表达组,比较总生存期和无进展生存期。在细胞实验中,将PC3细胞分为三组:NC组、BL组和miRNA组。检测不同组细胞的增殖、凋亡和周期情况,评估不同组PI3K、AKT和P21蛋白表达。
与良性前列腺增生相比,前列腺癌中微小RNA-27b表达显著增加()。与良性前列腺增生相比,前列腺癌组织中PI3K蛋白表达显著增强。癌组织中PI3K蛋白表达与miRNA-27b呈正相关。此外,微小RNA-27b表达与前列腺癌的Gleason分级和临床分期显著相关()。miR-27b表达水平较高的患者总生存期和无进展生存期均较差。在细胞实验中,miRNA组细胞增殖明显低于NC组();miRNA组细胞凋亡和G1期与NC组相比有显著差异();与NC组相比,miRNA组PI3K、AKT和P21蛋白表达显著下调()。
与良性前列腺增生组织相比,miR-27b在前列腺癌组织中上调,其表达水平与多种重要临床病理参数相关。在前列腺癌治疗中,抑制miR-27b可通过调节PI3K/AKT/P21信号通路抑制前列腺癌增殖。此外,miR-27b可能作为预测前列腺癌预后的有前景的生物标志物。